NCT06815770View on ClinicalTrials.gov

Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Acute on Chronic Liver Failure

Interventions

DRUG

Terlipressin Injectable Product

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors

lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT06815770 - Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed | Biotech Hunter | Biotech Hunter